Jennifer N Travis Seidl1, Paul J Massman2. 1. Department of Psychology, University of Houston, Houston, TX, USA jntravis@uh.edu. 2. Department of Psychology, University of Houston, Houston, TX, USA Department of Neurology, Alzheimer's Disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX, USA.
Abstract
BACKGROUND/AIMS: Previous research suggests that low levels of testosterone may be associated with the development of Alzheimer disease (AD), as well as poorer performance on certain neuropsychological tests and increased risk of depression. METHODS: This study utilized data from 61 nondemented older men and 68 men with probable AD. RESULTS: Testosterone levels did not differ between the groups. Regression analyses in men with AD revealed that testosterone levels did not significantly predict performance on neuropsychological tests or a measure of depression. Among controls, testosterone levels predicted estimated premorbid verbal IQ and performance on a verbal fluency test. CONCLUSION: Findings suggest that testosterone is not associated with most neuropsychological test performances in patients with AD.
BACKGROUND/AIMS: Previous research suggests that low levels of testosterone may be associated with the development of Alzheimer disease (AD), as well as poorer performance on certain neuropsychological tests and increased risk of depression. METHODS: This study utilized data from 61 nondemented older men and 68 men with probable AD. RESULTS:Testosterone levels did not differ between the groups. Regression analyses in men with AD revealed that testosterone levels did not significantly predict performance on neuropsychological tests or a measure of depression. Among controls, testosterone levels predicted estimated premorbid verbal IQ and performance on a verbal fluency test. CONCLUSION: Findings suggest that testosterone is not associated with most neuropsychological test performances in patients with AD.
Authors: Eka J Wahjoepramono; Prita R Asih; Vilia Aniwiyanti; Kevin Taddei; Satvinder S Dhaliwal; Stephanie J Fuller; Jonathan Foster; Malcolm Carruthers; Giuseppe Verdile; Hamid R Sohrabi; Ralph N Martins Journal: CNS Neurol Disord Drug Targets Date: 2016 Impact factor: 4.388